This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

Events Overview2nd ICPO Forum for Theranostics in Precision OncologyITM's ESMO 2021 Industry Satellite SymposiumITM Precision Oncology Symposium 2021COMPETE e-poster at AACR 2021

ITM's ESMO 2021 Industry Satellite Symposium

A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy

 

We would like to invite you to our virtual symposium “A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy” at the ESMO Congress 2021 on Friday September 17, 2021 from 10:30 am - 12:00 pm CEST, on channel 3.

The symposium will be chaired by Raj Srirajaskanthan, MD, FRCP, King’s College Hospital, London, UK who will introduce the expert speakers: Simron Singh, MD, MPH, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada; Namrata Vijayvergia, MD, FACP, Fox Chase Cancer Center, Philadelphia, U.S. and Grace Kong, MBBS (Hons), FRACP, FAANMS, Peter MacCallum Cancer Centre, Melbourne, Australia.

Targeted Radionuclide Therapy is rapidly becoming a new treatment paradigm in oncology, providing a targeted and precise therapeutic approach, as exemplified in this symposium by neuroendocrine tumors (NETs). As well as discussing the increasing prevalence of NETs and the evolution of treatment guidelines, an overview of the role of Targeted Radionuclide Therapy in clinical trials will be provided. In addition to the ongoing COMPETE trial, the new phase III trial COMPOSE, a prospective study in high Grade 2 and Grade 3 gastroenteropancreatic NETs, will be presented.

We look forward to welcoming you to join us in what promises to be an exciting overview of the current treatment options for patients with neuroendocrine tumors, with a particular focus on Targeted Radionuclide Therapy. This novel therapeutic approach is providing a paradigm shift in the management of patients with NETs and also for patients with other oncology conditions of high unmet medical need.

 

Scientific Program


Chair: Raj Srirajaskanthan, MD, FRCP
King’s College Hospital, London, UK
 

Welcome & Introduction
Raj Srirajaskanthan, MD, FRCP, King’s College Hospital, London, UK (5 min)

Changes in the Incidence and Prevalence of NETs – Impact of New Diagnostic Paradigms
Simron Singh, MD, MPH, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada (20 min)

The Evolution of Guidelines for the Treatment of NETs
Namrata Vijayvergia, MD, FACP, Fox Chase Cancer Center, Philadelphia, U.S. (20 min)

The Role of Targeted Radionuclide Therapy in Clinical Trials
Grace Kong, MBBS (Hons), FRACP, FAANMS, Peter MacCallum Cancer Centre, Melbourne, Australia (20 min)

Q&A and Closing Remarks (25 min)

 

Program for Download  Register at ESMO